vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and RESOURCES CONNECTION, INC. (RGP). Click either name above to swap in a different company.

RESOURCES CONNECTION, INC. is the larger business by last-quarter revenue ($117.7M vs $74.7M, roughly 1.6× Health Catalyst, Inc.). RESOURCES CONNECTION, INC. runs the higher net margin — -10.8% vs -121.9%, a 111.1% gap on every dollar of revenue. On growth, Health Catalyst, Inc. posted the faster year-over-year revenue change (-6.2% vs -19.2%). RESOURCES CONNECTION, INC. produced more free cash flow last quarter ($15.6M vs $9.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -11.8%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

RGP, formerly known as Resources Global Professionals, is the operating arm of Resources Connection, Inc.. The company provides consulting services in the areas of finance & accounting, information management, governance, risk & compliance (GRC), human capital, legal & regulatory, corporate advisory & restructuring, strategic communications, and supply chain management. As of fiscal year ending May 28, 2016, the company employed 3,283 professionals in 68 offices in 20 countries around the wor...

HCAT vs RGP — Head-to-Head

Bigger by revenue
RGP
RGP
1.6× larger
RGP
$117.7M
$74.7M
HCAT
Growing faster (revenue YoY)
HCAT
HCAT
+13.0% gap
HCAT
-6.2%
-19.2%
RGP
Higher net margin
RGP
RGP
111.1% more per $
RGP
-10.8%
-121.9%
HCAT
More free cash flow
RGP
RGP
$5.9M more FCF
RGP
$15.6M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-11.8%
RGP

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
HCAT
HCAT
RGP
RGP
Revenue
$74.7M
$117.7M
Net Profit
$-91.0M
$-12.7M
Gross Margin
37.1%
Operating Margin
-115.3%
-10.3%
Net Margin
-121.9%
-10.8%
Revenue YoY
-6.2%
-19.2%
Net Profit YoY
-340.3%
81.6%
EPS (diluted)
$-1.29
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
RGP
RGP
Q4 25
$74.7M
$117.7M
Q3 25
$76.3M
$120.2M
Q2 25
$80.7M
$139.3M
Q1 25
$79.4M
$129.4M
Q4 24
$79.6M
$145.6M
Q3 24
$76.4M
$136.9M
Q2 24
$75.9M
$148.2M
Q1 24
$74.7M
$151.3M
Net Profit
HCAT
HCAT
RGP
RGP
Q4 25
$-91.0M
$-12.7M
Q3 25
$-22.2M
$-2.4M
Q2 25
$-41.0M
$-73.3M
Q1 25
$-23.7M
$-44.1M
Q4 24
$-20.7M
$-68.7M
Q3 24
$-14.7M
$-5.7M
Q2 24
$-13.5M
$10.5M
Q1 24
$-20.6M
$2.5M
Gross Margin
HCAT
HCAT
RGP
RGP
Q4 25
37.1%
Q3 25
52.6%
39.5%
Q2 25
40.2%
Q1 25
35.1%
Q4 24
38.5%
Q3 24
47.5%
36.5%
Q2 24
40.2%
Q1 24
37.0%
Operating Margin
HCAT
HCAT
RGP
RGP
Q4 25
-115.3%
-10.3%
Q3 25
-22.9%
-1.7%
Q2 25
-46.0%
-47.0%
Q1 25
-25.4%
-38.4%
Q4 24
-22.0%
-52.7%
Q3 24
-17.9%
-3.5%
Q2 24
-20.8%
7.6%
Q1 24
-30.5%
2.8%
Net Margin
HCAT
HCAT
RGP
RGP
Q4 25
-121.9%
-10.8%
Q3 25
-29.1%
-2.0%
Q2 25
-50.8%
-52.6%
Q1 25
-29.9%
-34.0%
Q4 24
-26.0%
-47.2%
Q3 24
-19.3%
-4.2%
Q2 24
-17.8%
7.1%
Q1 24
-27.6%
1.7%
EPS (diluted)
HCAT
HCAT
RGP
RGP
Q4 25
$-1.29
$-0.38
Q3 25
$-0.32
$-0.07
Q2 25
$-0.59
$-2.21
Q1 25
$-0.35
$-1.34
Q4 24
$-0.33
$-2.08
Q3 24
$-0.24
$-0.17
Q2 24
$-0.23
$0.31
Q1 24
$-0.35
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
RGP
RGP
Cash + ST InvestmentsLiquidity on hand
$95.7M
$89.8M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$194.6M
Total Assets
$502.6M
$289.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
RGP
RGP
Q4 25
$95.7M
$89.8M
Q3 25
$91.5M
$77.5M
Q2 25
$97.3M
$86.1M
Q1 25
$342.0M
$72.5M
Q4 24
$392.0M
$78.2M
Q3 24
$387.3M
$89.6M
Q2 24
$308.3M
$108.9M
Q1 24
$327.8M
$113.8M
Total Debt
HCAT
HCAT
RGP
RGP
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
RGP
RGP
Q4 25
$245.8M
$194.6M
Q3 25
$331.9M
$206.4M
Q2 25
$347.5M
$207.1M
Q1 25
$376.8M
$277.8M
Q4 24
$365.2M
$325.7M
Q3 24
$355.0M
$407.2M
Q2 24
$357.0M
$418.8M
Q1 24
$357.2M
$414.9M
Total Assets
HCAT
HCAT
RGP
RGP
Q4 25
$502.6M
$289.3M
Q3 25
$587.1M
$287.2M
Q2 25
$616.2M
$304.7M
Q1 25
$891.5M
$375.6M
Q4 24
$858.9M
$424.9M
Q3 24
$813.0M
$512.9M
Q2 24
$691.7M
$510.9M
Q1 24
$695.1M
$523.2M
Debt / Equity
HCAT
HCAT
RGP
RGP
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
RGP
RGP
Operating Cash FlowLast quarter
$9.9M
$15.9M
Free Cash FlowOCF − Capex
$9.6M
$15.6M
FCF MarginFCF / Revenue
12.9%
13.2%
Capex IntensityCapex / Revenue
0.4%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$24.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
RGP
RGP
Q4 25
$9.9M
$15.9M
Q3 25
$-464.0K
$-7.8M
Q2 25
$-9.0M
$16.8M
Q1 25
$280.0K
$659.0K
Q4 24
$-3.5M
$1.8M
Q3 24
$6.2M
$-309.0K
Q2 24
$1.6M
$3.2M
Q1 24
$10.3M
$20.5M
Free Cash Flow
HCAT
HCAT
RGP
RGP
Q4 25
$9.6M
$15.6M
Q3 25
$-719.0K
$-8.0M
Q2 25
$-9.2M
$16.5M
Q1 25
$-390.0K
$238.0K
Q4 24
$-3.9M
$61.0K
Q3 24
$5.5M
$-575.0K
Q2 24
$1.3M
$3.0M
Q1 24
$10.1M
$20.4M
FCF Margin
HCAT
HCAT
RGP
RGP
Q4 25
12.9%
13.2%
Q3 25
-0.9%
-6.6%
Q2 25
-11.4%
11.8%
Q1 25
-0.5%
0.2%
Q4 24
-4.9%
0.0%
Q3 24
7.2%
-0.4%
Q2 24
1.7%
2.1%
Q1 24
13.5%
13.5%
Capex Intensity
HCAT
HCAT
RGP
RGP
Q4 25
0.4%
0.3%
Q3 25
0.3%
0.1%
Q2 25
0.3%
0.2%
Q1 25
0.8%
0.3%
Q4 24
0.5%
1.2%
Q3 24
0.9%
0.2%
Q2 24
0.4%
0.1%
Q1 24
0.3%
0.1%
Cash Conversion
HCAT
HCAT
RGP
RGP
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.30×
Q1 24
8.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

RGP
RGP

US$93.7M80%
Non Us$24.0M20%

Related Comparisons